.Attributes Medication, Released online: 16 September 2024 doi:10.1038/ s41591-024-03244-8In the empirical SCRUM-Japan GOZILA research study, after a median consequence of 11 months, people with metastatic stomach lumps who received biomarker-matched therapies based on spreading cyst DNA profiling revealed a more significant medical perk than those obtaining unequaled therapy.